| Author | Year | Study Design | N˚ and characteristic of the population | Main exclusion criterion | Follow-up | Intervention | Results |
| Mezzana et al. | 2022 | Retrospective | 54 women between 40 and 71 years old, with normal CMI and SUI |
| 4 mo | Bipolar RF in all patients, at anterior portion of the middle and distal thirds of the vagina, temp between 41˚C - 44˚C, 2 sessions, 4 weeks apart | SUI improvement in volume from “moderate quantitaty” to “none” Reduction in Loss frequency from 2.1 weekly to 0.8×. |
| Ribeiro et al. | 2021 | Systematic Review | Women with UI treated with any type of RF as intervention | Studies conducted for less than 3 months; animal or in vitro studies; articles whose main objective was to evaluate the use of other types of energy in the treatment of UI; articles targeting vaginal rejuvenation, fecal incontinence, vaginal atrophy and other urinary tract diseases | Studies conducted between 2016 and 2021 | Any type of RF, compared to other treatments, including placebo, vaginal estrogen, PFME, or no treatment | studies have shown significant improvement in SUI-related symptoms. |
| Ahmed Abdelaziz et al. | 2021 | Retrospective | 101 women with SUI or MUI | Women with previous surgery for SUI, prolapse greater than stage II, neurological disease, pregnant and nursing women. | 6 mo | 69 patients treated with bipolar RF, 32 patients with monopolar RF. 3 sessions of 7 - 10 minutes, 4 weeks apart, temp 43˚C | symptom improvement in both monopolar and bipolar RF groups. |
| Slongo et al. | 2022 | Randomized clinical trial | 117 climacteric women aged 45 - 65 years with SUI | Patients with prolapse grade 3 or higher, previous surgery for prolapse, PMFE within the past 12 months, use of vaginal estrogen or HT within the past 6 months. | 30 days | Group 1:3 monthly microablativa RF sessions; Group 2: weekly PMFE for 12 weeks; Group 3: both therapies | RF associated with PMFE obtained better results than PMFE of RF alone. |
| Pinheiro et al. | 2021 | Pilot Study | 11 menopausal women with complaint of GSM | HT within previous 6 months, pacemaker carriers, pelvic metal, hemophiliacs, vasodilators or anticoagulants users, degenerative neurological disease, vaginal infection. | 3 mo | RF non-ablative at 41˚C. 5 weekly sessions of 4 minutes. | clinical improvement in symptoms of UI, vaginal dryness, dyspareunia, pruritus, burning and sexual dysfunction |